Stroma targeting nuclear imaging and radiopharmaceuticals

Area of Science:

• Oncology
• Nuclear Medicine
• Medical Imaging

Background:

• Tumor microenvironment changes are crucial for cancer progression, including local growth, invasion, and metastasis.
• Nuclear imaging techniques, such as Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT), provide functional and biochemical insights into tissues.
• While [(18)F]fluorodeoxyglucose ([(18)F]FDG)-PET/CT is valuable, it lacks target specificity for tumor microenvironment components.

Purpose of the Study:

• To review tumor microenvironment-targeting oncologic imaging strategies.
• To explore therapeutic radiopharmaceuticals for enhanced cancer management.
• To provide a roadmap for future applications in tumor imaging and therapy.

Main Methods:

• Literature review of current research on tumor microenvironment imaging.
• Analysis of PET/SPECT tracers targeting specific tumor characteristics (angiogenesis, invasion, hypoxia, growth, homing).
• Examination of therapeutic radiopharmaceuticals for combined imaging and treatment.

Main Results:

• The tumor stroma plays a significant role in cancer progression and metastasis.
• Target-specific PET/SPECT tracers offer advantages over non-specific tracers like [(18)F]FDG for detailed tumor characterization.
• Emerging imaging agents can visualize key aspects of the tumor microenvironment, guiding therapeutic decisions.

Conclusions:

• Targeting the tumor microenvironment with advanced nuclear imaging offers significant potential for improving cancer diagnosis and treatment.
• Further development of specific radiotracers and therapeutic radiopharmaceuticals is essential for personalized oncology.
• This review highlights the expanding role of nuclear imaging in comprehending and combating cancer through microenvironment targeting.